The ASCO Post Staff
Gaurav Goyal, MD, of the University of Alabama at Birmingham, reports on findings from a large multi-institutional database study, which showed there was no apparent difference in overall survival between R-CHOP and R-EPOCH among patients with advanced-stage MYC-rearranged, double-hit, or triple-hit diffuse large B-cell lymphoma. Further studies are needed for better risk stratification to optimize outcomes (Abstract S224).
The ASCO Post Staff
Cristina Gasparetto, MD, of Duke University, discusses findings from a study that suggests patients with heavily pretreated multiple myeloma benefit from weekly selinexor, carfilzomib, and dexamethasone, which was reported to be active, with an overall response rate of 78% and an overall progression-free survival of 23 months (Abstract S188).
The ASCO Post Staff
Martin Kaiser, MD, of The Institute of Cancer Research and Royal Marsden Hospital, discusses findings from the UK OPTIMUM/MUKNINE trial on the depth of response and minimal residual disease status in patients with ultra-high–risk newly diagnosed multiple myeloma and plasma cell leukemia who were treated with augmented autologous transplant and daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone (Abstract S181).
The ASCO Post Staff
Martin Hutchings, MD, PhD, of Copenhagen University Hospital, discusses a 5-year update of the phase III ECHELON-1 study, which suggested brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine benefits patients with previously untreated stage III or IV classical Hodgkin lymphoma (Abstract S205).
The ASCO Post Staff
Martin H. Dreyling, MD, PhD, of University Hospital Munich Grosshadern Klinikum, discusses phase II results from the ELARA trial, which suggests tisagenlecleucel may be a promising immunotherapy for adults with relapsed or refractory follicular lymphoma (Abstract S210).
